SNPs passing the meta P < .001
| Gene . | rs ID . | Chrom . | Odds . | P . | 95% CI . | MAF . | |
|---|---|---|---|---|---|---|---|
| No inhibitor (n = 376) . | Inhibitor (n = 457) . | ||||||
| MAPK9 | rs4147385 | 5 | 2.03 | 9.57 × 10−06 | 1.48-2.78 | 15.6% | 22.1% |
| PDGFRB | rs10072056 | 5 | 0.61 | 3.87 × 10−05 | 0.48-0.77 | 29.1% | 27.0% |
| PCGF2 | rs2879097 | 17 | 0.58 | 4.69 × 10−05 | 0.45-0.76 | 26.9% | 22.3% |
| DOCK2 | rs1863993 | 5 | 4.29 | 7.37 × 10−05 | 2.09-8.80 | 1.5% | 2.7% |
| CD44 | rs927335 | 11 | 1.67 | 1.86 × 10−04 | 1.28-2.19 | 28.8% | 36.5% |
| IQGAP2 | rs17652304 | 5 | 3.65 | 3.19 × 10−04 | 1.80-7.40 | 2.3% | 4.1% |
| CSF1R | rs17725712 | 5 | 2.39 | 3.72 × 10−04 | 1.48-3.86 | 6.3% | 10.2% |
| HSP90B1 | rs1882019 | 12 | 0.56 | 6.04 × 10−04 | 0.40-0.78 | 12.7% | 8.6% |
| F13A1 | rs13206518 | 6 | 0.44 | 6.75 × 10−04 | 0.28-0.71 | 6.6% | 4.1% |
| IGSF2 | rs2296449 | 1 | 0.34 | 7.16 × 10−04 | 0.18-0.63 | 4.8% | 3.1% |
| ALOX5AP | rs4075131 | 13 | 0.63 | 8.40 × 10−04 | 0.48-0.82 | 30.1% | 25.7% |
| MAP2K4 | rs3826392 | 17 | 0.67 | 9.74 × 10−04 | 0.52-0.85 | 29.1% | 23.2% |
| PTPRN2 | rs12667537 | 7 | 0.66 | 9.95 × 10−04 | 0.51-0.84 | 47.7% | 41.3% |
| Gene . | rs ID . | Chrom . | Odds . | P . | 95% CI . | MAF . | |
|---|---|---|---|---|---|---|---|
| No inhibitor (n = 376) . | Inhibitor (n = 457) . | ||||||
| MAPK9 | rs4147385 | 5 | 2.03 | 9.57 × 10−06 | 1.48-2.78 | 15.6% | 22.1% |
| PDGFRB | rs10072056 | 5 | 0.61 | 3.87 × 10−05 | 0.48-0.77 | 29.1% | 27.0% |
| PCGF2 | rs2879097 | 17 | 0.58 | 4.69 × 10−05 | 0.45-0.76 | 26.9% | 22.3% |
| DOCK2 | rs1863993 | 5 | 4.29 | 7.37 × 10−05 | 2.09-8.80 | 1.5% | 2.7% |
| CD44 | rs927335 | 11 | 1.67 | 1.86 × 10−04 | 1.28-2.19 | 28.8% | 36.5% |
| IQGAP2 | rs17652304 | 5 | 3.65 | 3.19 × 10−04 | 1.80-7.40 | 2.3% | 4.1% |
| CSF1R | rs17725712 | 5 | 2.39 | 3.72 × 10−04 | 1.48-3.86 | 6.3% | 10.2% |
| HSP90B1 | rs1882019 | 12 | 0.56 | 6.04 × 10−04 | 0.40-0.78 | 12.7% | 8.6% |
| F13A1 | rs13206518 | 6 | 0.44 | 6.75 × 10−04 | 0.28-0.71 | 6.6% | 4.1% |
| IGSF2 | rs2296449 | 1 | 0.34 | 7.16 × 10−04 | 0.18-0.63 | 4.8% | 3.1% |
| ALOX5AP | rs4075131 | 13 | 0.63 | 8.40 × 10−04 | 0.48-0.82 | 30.1% | 25.7% |
| MAP2K4 | rs3826392 | 17 | 0.67 | 9.74 × 10−04 | 0.52-0.85 | 29.1% | 23.2% |
| PTPRN2 | rs12667537 | 7 | 0.66 | 9.95 × 10−04 | 0.51-0.84 | 47.7% | 41.3% |
SNPs passing the meta P < .001, having odds in the same direction in all 3 cohorts, or allowing for a 20% interval around an OR of 1 in 1 of the 3 and 2 cohorts having significance at α = 0.05.